SynthesisEuropean journal of medical research2025
The impact of abrocitinib treatment on lesion area and pruritus in patients with atopic dermatitis: a systematic review and meta-analysis.
Synthesis in European journal of medical research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Calcineurin Inhibitors in Atopic Dermatitis: Balancing Tradition with Emerging Therapeutics.Medical sciences (Basel, Switzerland) · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundAtopic dermatitis (AD) is a chronic inflammatory skin disorder characterized by intense itching and lesions that significantly impact patients' quality of life. Abrocitinib, a selective Janus kinase 1 (JAK1) inhibitor, has shown promise in treating AD by targeting inflammatory pathways linked to disease symptoms. This systematic review and meta-analysis evaluates the effectiveness of abrocitinib in reducing lesion severity and pruritus in AD patients.
methodsA systematic search of PubMed, Embase, Web of Science, and Cochrane Library was conducted on September 19, 2024, following Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines. Included studies were randomized controlled trials assessing abrocitinib's effects on lesion area and pruritus in AD patients. Data extraction and quality assessment were performed using the Cochrane risk of bias tool. Statistical analyses, including meta-regression and subgroup analysis, were conducted using Stata. Funnel plots were examined to assess publication bias.
resultsFive studies met inclusion criteria, with sample sizes ranging from 267 to 837 participants. Abrocitinib significantly improved Investigator's Global Assessment (IGA) and Eczema Area and Severity Index (EASI-75) scores, as well as pruritus scores on the Pruritus Patient Numeric Rating Scale (PP-NRS), compared to placebo (all P < 0.001). A dose-response effect was observed, with higher efficacy at the 200 mg dose. The incidence of treatment-emergent adverse events (TEAEs) was higher in the intervention group, particularly at 200 mg, though no significant difference was noted in serious adverse events (SAEs) between groups.
conclusionsAbrocitinib is effective in reducing lesion severity and pruritus in AD, with dose-dependent improvements. Despite a higher incidence of manageable TEAEs at 200 mg, no significant increase in SAEs was observed, supporting abrocitinib's safety and efficacy as a treatment for moderate to severe AD. REGISTRATION: CRD420251056272.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.